CHENNAI PRESS NEWS

Asset Quality and Capital Adequacy Improve Chennai, May, 2019: Indian Bank posted strong growth in FY 2018-19 with Global Business witnessing a 16% jump over last year to Rs. 4.29 lakh crores. Deposits grew by 16% to Rs. 2.42 lakh crores and Advances by 15% to Rs. 1.87 lakh crores. The Advances portfolio was driven by 18% increase in RAM (Retail-Agri-MSME) lending and 12% increase in Corporate lending. Further, the overall loan book continued to be well-diversified with a 58% skew towards the RAM Sector. Bank remained diligent in pursuing operational efficiency and clocked a 12% Y-o-Y increase in Net Interest Income, with Domestic NIM at 3%. (L-R) M.K.Bhattacharya, Executive Direcor, Padmaja Chunduru, Managing Director,  V.V.Shenoy, Executive Director Bank’s CRAR at 13.21% was higher by 66 bps Y-o-Y. Its well-capitalized base has been further augmented by the recently- launched ESPS (Employee Stock Purchase Scheme) which has been successfully completed with...

Launch the HCL Squash Podium Program to improve both player and coaching standards with the aim of getting more Indian players to finish at the podium Chennai, May 15, 2019:   HCL, a leading global conglomerate, today announced the launch of HCL Squash Podium Program in partnership with the Squash Rackets Federation of India (SRFI) to significantly improve the Squash ecosystem in India. The multi-pronged program will focus on driving a 360-degree overhaul in Indian Squash by improving both player (senior and junior) and coaching standards and enhancing the overall prominence of the sport in the country. As part of this initiative, HCL and SRFI will also host the HCL Indian Tour - a Professional Squash Association (PSA) multi-city circuit in the country, giving the Indian players an opportunity to compete against the world’s best on their home turf. The year-long HCL Squash Podium Program will host:- Multiple coaching camps and referee clinics – HCL and SRFI will work...

Glenmark Pharmaceuticals today announced the launch of its novel, patent protected and globally-researched sodium glucose co-transporter (SGLT2) inhibitor Remogliflozinetabonate (Remogliflozin) in Tamil Nadu   According ICMR-INDIAB study, prevalence of diabetes in Tamil Nadu is around 10.4%. In South Chennai, the prevalence of diabetes in people under 50 years was more than 20% and over 65% of the known diabetics have uncontrolled sugar values of >200 mg/dl according to a study published in the I nternational Journal of Community Medicine and Public Health India is the first country to get access to Remogliflozin, aninnovative, patent-protected sodium glucose co-transporter-2 (SGLT2) inhibitor indicated in the treatment of type-2 diabetes mellitusin adults Glenmark’s Remogliflozin is priced over 50% lower than the existing SGLT2 inhibitors in India Chennai , India; May 15, 2019: Glenmark Pharmaceuticals Ltd (Glenmark), a research-led global integrat...